AI Article Synopsis
- * A total of 54 patients were retreated with either standard therapy (pegylated interferon and ribavirin) or intensive treatment, revealing an overall SVR rate of 75.92%.
- * Findings suggested that retreatment can lead to SVR rates between 60%-90%, with higher success in relapsed patients compared to non-responders, indicating specific groups that may benefit more from intensive retreatment.
Article Abstract
Objective: To explore the retreatment of CHC patients with initial treatment failure and how to achieve SVR.
Methods: 54 patients who had experienced treatment failure were enrolled and retreated with standard treatment of pegylated interferon and ribavirin or intensive treatment, respectively. Their SVR rates were statistically compared, to decide two therapies' application.
Results: 54 patients had been retreated, and total SVR rate was up to 75.92%, with 88.46% in relapsed patients and 64.29% in non-responders. After retreatment with pegylated interferon and ribavirin, SVR rate was 95.45% in patients with prior interferon monotherapy, and 64.71% in patients with prior interferon and ribavirin, and 60% in patients with prior pegylated interferon alpha-2a monotherapy. SVR rate of relapsed patients was significantly higher than that of non-responders.
Conclusions: In CHC patients with treatment failure, SVR rate of retreatment with standard treatment or intensive treatment still can be up to 60%-90%. Retreatment with standard therapy can be applied to patients who had received interferon monotherapy or interferon plus ribavirin. Three types of patients who need intensive retreatment were as following: patients nonresponsive to interferon plus ribavirin or pegylated interferon alpha-2a monotherapy, and patients with treatment failure who had received prior standard treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY).
J Gastrointestin Liver Dis
December 2024
Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Background And Aims: Pan-genotypic ribavirin-free oral direct-acting antivirals, including the glecaprevir/pibrentasvir combination, are recommended for the treatment of most patients with chronic hepatitis C virus (HCV) infection. In Romania, the HCV-infected patient population receiving glecaprevir/pibrentasvir is not well characterized and data on treatment effectiveness is lacking. The ODYSSEY study aimed to provide insights into the characteristics and treatment outcomes of HCV-infected Romanian patients receiving 8-week therapy with glecaprevir/pibrentasvir.
View Article and Find Full Text PDFA Glimpse for the subsistence from pandemic SARS-CoV-2 infection.
Bioorg Chem
January 2025
School of Pharmaceuticals and Population Health Informatics, Faculty of Pharmacy, DIT University, Dehradun, Uttarakhand, 248009, India.
COVID-19 is an emerging viral pandemic caused by SARS-CoV-2, which is the causative agent of unprecedented disease-causing public health threats globally. Worldwide, this outbreak is wreaking havoc due to failure in risk assessment regarding the urgency of the pandemic. As per the reports, many secondary complications which include neurological, nephrological, gastrointestinal, cardiovascular, immune, and hepatic abnormalities, are linked with COVID -19 infection which is associated with prominent respiratory disorders including pneumonia.
View Article and Find Full Text PDFA Scoping Review of Arthropod-Borne Flavivirus Infections in Solid Organ Transplant Recipients.
Transpl Infect Dis
December 2024
Department of Medicine, Division of Infectious Diseases, Cooper Medical School of Rowan University, Camden, New Jersey, USA.
Arthropod-borne flaviviruses (ABFs), transmitted by mosquitoes or ticks, are increasing due to climate change and globalization. This scoping review examines the epidemiology, clinical characteristics, diagnostics, treatment, and outcomes of ABF infection in solid organ transplant recipients (SOTRs). A database search up to January 25, 2024, focused on ABFs such as West Nile virus (WNV), dengue virus (DENV), Japanese encephalitis virus (JEV), Powassan virus (POWV), yellow fever virus (YFV), and Zika virus (ZIKV), limited to SOTRs.
View Article and Find Full Text PDFAcute effects of interferon-alpha on cellular anabolic and catabolic processes are associated with the development of fatigue during Interferon-alpha-based therapy for Hepatitis-C: A preliminary study.
Brain Behav Immun
January 2025
CUBRIC, Cardiff University Brain Research Imaging Centre, Cardiff, UK; Clinical Imaging Sciences Centre, Brighton and Sussex Medical School, Brighton, UK.
Introduction: Interferon-alpha (IFN-α) is a key mediator of antiviral immune responses used to treat Hepatitis-C virus (HCV) infection. Though clinically effective, IFN-α frequently induces functionally impairing mood and motivation symptoms, particularly fatigue. Unlike mood impairment, which typically emerges after weeks of treatment, fatigue tends to emerge and evolve rapidly, typically within hours of the first IFN-α injection.
View Article and Find Full Text PDFThe Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study.
Genes (Basel)
August 2024
Internal Medicine Unit, Maggiore della Carità Hospital, 28100 Novara, Italy.
Article Synopsis
- Direct-acting antivirals (DAAs) have made hepatitis C treatment much easier, but there’s limited info on how they work for patients with glucose-6-phosphate dehydrogenase deficiency (G6PDd).
- A study looked at 2754 HCV-positive patients from 2015 to 2023, focusing on 38 with confirmed G6PDd, while monitoring their health closely during and after treatment.
- Results showed no significant health issues or adverse events related to the treatment, with effectiveness similar to those without G6PDd, indicating that DAAs are safe for HCV treatment in these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!